A phase 1/2 study of PGN004, a recombinant human alpha-glucosidase for Pompe disease.
Phase of Trial: Phase I/II
Latest Information Update: 02 Aug 2018
Price : $35 *
At a glance
- Drugs PGN 004 (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions
- 02 Aug 2018 New trial record
- 26 Jul 2018 According to a Pharming Group NV media release, the application for this study will be submitted in early 2019.